Navigation Links
New CyberKnife Technologies Demonstrate Dramatic Reduction in Treatment Times
Date:8/5/2008

First Patients Treated Using Next Generation CyberKnife System at Oklahoma

CyberKnife Center

SUNNYVALE, Calif., Aug. 5 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that the first patients were treated using the next generation CyberKnife(R) Robotic Radiosurgery System that was recently installed at the Oklahoma CyberKnife, LLC in Tulsa, OK. The next generation CyberKnife System, which features new technologies and system upgrades announced at the 2007 American Society for Therapeutic Radiology and Oncology Annual Meeting, is capable of delivering state-of-the-art radiosurgery with significantly reduced treatment planning and delivery times.

Treatment results on the Oklahoma CyberKnife, LLC's first day were ground-breaking. While treatment times will vary based upon case complexity and type of cancer, the first patient treated for an intracranial lesion was completed in only 16 minutes. The next patient, treated for non-small cell lung cancer, required only 27 minutes of treatment time.

Incorporating all of the newest enhancements, the next generation CyberKnife System achieved a considerable reduction in treatment times. Using the latest advancement in treatment planning, Sequential Optimization enabled treatment plans to be developed in as little as 15 minutes. With the new 800 monitor unit/minute linear accelerator treatment times were reduced with a 30 percent faster rate of dose delivery as compared to previous systems. Further, the recently launched Iris(TM) Variable Aperture Collimator enabled very conformal, multi-collimator treatments to be rapidly delivered to even the most complex targets. And with the
'/>"/>

SOURCE Accuray Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. M. D. Anderson Cancer Center to Lead Study of Surgery vs. CyberKnife(R) Radiosurgery for Operable Lung Cancer Patients
2. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
3. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
4. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
5. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
6. New Clinical Studies Confirm Mauna Kea Technologies Cellvizio(R) GI in Range of Procedures
7. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
8. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
9. Senesco Technologies Initiates Preclinical Studies for Cancer Target
10. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
11. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... March 3, 2015  American Biosurgical, LLC ("ABI") ... cable manufacturer actively engaged in the design, development ... the world,s leading medical device companies has announced ... low volume custom medical cable manufacturer based in ... MTI brand under the name MTI Medical Cables.  ...
(Date:3/3/2015)... -- Columbia Laboratories, Inc. (Nasdaq: CBRX ) (" ... pharmaceutical company focused on pharmaceuticals for women,s health, today ... ROTH Conference, which will take place from March 8-11 ... Point, California . Management,s presentation will take place ... (12:00 p.m. Eastern Time) in the Promenade room. ...
(Date:3/3/2015)... - Sante Medical Hair Restoration is now offering the ... The ARTAS Robotic System is a state-of-the-art ... for transplantation. This latest development in minimally-invasive hair ... linear scar. "The ARTAS technology extends ... surgery." says Dr. Louis Grondin , Medical ...
Breaking Medicine Technology:American Biosurgical Acquires MTI Corporation 2No linear scar. Permanent results. 2
... Children,s Oncology Group Report Shows the Addition of ... of Death by 30% in Osteosarcoma Patients, ... IDMI ) today announced the Journal of ... 3 mifamurtide (L-MTP-PE) clinical trial,(INT-0133), entitled "Osteosarcoma: The ...
... Show Subjects Receiving,Infrequently Administered Ustekinumab Maintained Improvement from Psoriasis ... ... SAN ANTONIO, Feb. 2 One-year data from a second,double-blind, ... weeks provided sustained, clinically meaningful,improvement in the treatment of moderate ...
Cached Medicine Technology:IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 2IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 3IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 4IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 5IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 6IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 7Ustekinumab (CNTO 1275) Phase 3 Data Show Long-Term Improvement Of Chronic Plaque Psoriasis 2Ustekinumab (CNTO 1275) Phase 3 Data Show Long-Term Improvement Of Chronic Plaque Psoriasis 3Ustekinumab (CNTO 1275) Phase 3 Data Show Long-Term Improvement Of Chronic Plaque Psoriasis 4Ustekinumab (CNTO 1275) Phase 3 Data Show Long-Term Improvement Of Chronic Plaque Psoriasis 5
(Date:3/3/2015)... 03, 2015 On February 21st, the ... fabulous EcoLuxe Lounge, a day-long event that features a ... products and services. Organized by Debbie Durkin and Durkin ... placement producer, the EcoLuxe Lounge saw many notable attendees. ... on General Hospital, The Flash, Star Trek: Deep Space ...
(Date:3/3/2015)... CA (PRWEB) March 03, 2015 Findings ... , Researchers at UC Davis have developed and characterized ... cancer cells, causing them to self-destruct. This novel mechanism ... responsible for a usually fatal type of brain cancer ... cancers. , The article, to be published in ...
(Date:3/3/2015)... The Rheumatology Nurses Society (RNS) ... care and safe practice for patients with rheumatic diseases. ... biologic infusions are administered in an infusion center, provider’s ... registered nurse (RN), as defined in their State Nurse ... patients receiving these medications during a first infusion, as ...
(Date:3/3/2015)... TX (PRWEB) March 04, 2015 The ... information on the therapeutic development for Alopecia. Alopecia is ... are the two main types of alopecia. Causes for ... disorder. Symptoms of alopecia may include male pattern hair ... broken hair. Alopecia can be classified as focal or ...
(Date:3/3/2015)... March 03, 2015 Daylight Savings Time may ... Kothare, MD, has tips for parents. , Parents and their ... at 2:00 a.m. when they set their clocks forward one ... up that day -- one hour earlier -- you will ... parents should start thinking about “sleep hygiene” for their kids ...
Breaking Medicine News(10 mins):Health News:Hollywood Star Chase Masterson and Choices Recovery Discuss Substance Abuse and Treatment at 2015 Oscars 2Health News:News: UC Davis Scientists Describe Novel Drug Mechanism That Fights Brain Cancer 2Health News:News: UC Davis Scientists Describe Novel Drug Mechanism That Fights Brain Cancer 3Health News:News: UC Davis Scientists Describe Novel Drug Mechanism That Fights Brain Cancer 4Health News:Administration of Biologic Infusions: A Position Statement of the Rheumatology Nurses Society 2Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 2Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 3Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 4Health News:Don’t Let Daylight Savings Disrupt Your Child’s Sleep 2
... Researchers at The Wistar Institute announce the discovery of ... with human papillomavirus (HPV). Their results, in both ... inhibitors protect a tumor-suppressing protein targeted by viral proteins, ... scientists presented their findings in the April 20 issue ...
... are testing whether different doses of an established blood pressure ... in people with mild hypertension, possibly with fewer side effects ... funded with a $1.9 million grant from the National Heart ... in the United States. The study drug, carvedilol ...
... April 26 (HealthDay News) -- The fourth National Prescription Drug ... 2 p.m., the U.S. Drug Enforcement Administration says. The ... and unused prescription drugs. At the third Take-Back Day ... tons) of unwanted or expired medications at more than 5,300 ...
... WEDNESDAY, April 25 (HealthDay News) -- Urban areas contaminated decades ... of aggravated assault, according to a new study. The ... dust emitted from older vehicles that ran on leaded gasoline, ... paint could have played a role as well. ...
... rs1051730-rs16969968 genotype and objective measures of tobacco exposure, which ... entirely, mediated by level of tobacco exposure, according to ... of the National Cancer Institute . The rs1051730-rs16969968 ... smoking, lung cancer risk, and other smoking-related outcomes. Prior ...
... are proposing a new model of care collaboration ... with various emergent cardiovascular conditions which require rapid, ... mortality, in an article published April 24 in ... ST-segment elevation myocardial infarction (STEMI), non-STEMI/unstable angina, out-of-hospital ...
Cached Medicine News:Health News:Small molecular bodyguards kill HPV-infected cancer cells by protecting tumor-suppressor 2Health News:Small molecular bodyguards kill HPV-infected cancer cells by protecting tumor-suppressor 3Health News:URMC clinical trial tests new regimen for hypertension 2Health News:Leaded Gas Exposure Linked to Later Violence: Study 2Health News:Genetic variants, tobacco exposure and lung cancer risk 2Health News:Is it time for regional cardiovascular emergency care systems across the US? 2
... low cost, low volume alternative. Whole blood is ... separated from whole blood by centrifugation in a ... the Cebus single use cartridge. The cartridge is ... activate the concentrating process. Finally, the cartridge is ...
Avitene Microfibrillar Collagen Hemostat (MCH) is used in surgical procedures as an to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical....
... device restores lordosis and ... less reaming of the ... Danek's Tapered Laparoscopic Instruments ... and reproducibly place the ...
3D Cranial is the most widely used surgical navigation software. Navigate with confidence and ease with displayed Zone of Accuracy and several fully automated features. 3D Cranial offers seamless int...
Medicine Products: